A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable

Site 1, Vienna

Site 2, Vienna

Brussels

Leuven

Loverval

Site 1, Berlin

Site 2, Berlin

Site 3, Berlin

Site 4, Berlin

Site 5, Berlin

Site 6, Berlin

Site 7, Berlin

Bochum

Site 1, Dresden

Site 2, Dresden

Site 3, Dresden

Erlangen

Frankfurt am Main

Site 1, Hamburg

Site 2, Hamburg

Heidelberg

Kiel

Langenau

Leipzig

Lübeck

Magdeburg

Mahlow

Mainz

Site 1, München

Site 2, München

Münster

Osnabrück

Selters

Stuttgart

Tübingen

Dublin

Amsterdam

Utrecht

Site 1, Bialystok

Site 1, Bydgoszcz

Site 2, Bydgoszcz

Gdansk

Site 1, Katowice

Site 2, Katowice

Site 3, Katowice

Kielce

Site 1, Krakow

Site 2, Krakow

Site 1, Lodz

Site 2, Lodz

Site 3, Lodz

Lublin

Szczecin

Site 1, Warsaw

Site 2, Warsaw

Warsaw

Site 1, Wroclaw

Site 2, Wroclaw

Zgierz

Chelyabinsk

Kazan'

Moscow

Ryazan

Saint Petersburg

Košice

Svidník

Site 1, Barcelona

Site 2, Barcelona

Site 1, London

Site 2, London

Oxford

Portsmouth

Sheffield